Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Liabilities and Shareholders Equity (2016 - 2025)

Mimedx's Liabilities and Shareholders Equity history spans 15 years, with the latest figure at $342.7 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 29.83% year-over-year to $342.7 million; the TTM value through Dec 2025 reached $1.2 billion, up 27.46%, while the annual FY2025 figure was $342.7 million, 29.83% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $342.7 million at Mimedx, up from $319.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $342.7 million in Q4 2025 and bottomed at $168.2 million in Q1 2023.
  • The 5-year median for Liabilities and Shareholders Equity is $230.2 million (2024), against an average of $233.1 million.
  • The largest annual shift saw Liabilities and Shareholders Equity dropped 9.87% in 2022 before it surged 39.44% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $187.9 million in 2021, then fell by 8.78% to $171.4 million in 2022, then surged by 39.44% to $239.0 million in 2023, then increased by 10.4% to $263.9 million in 2024, then increased by 29.83% to $342.7 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Liabilities and Shareholders Equity are $342.7 million (Q4 2025), $319.0 million (Q3 2025), and $291.1 million (Q2 2025).